The Plymouth Group, which owns the property, has partnered with Centerbridge Partners, L.P. to turn the former Budd Plant in Philadelphia into a facility that will support biomanufacturing efforts of companies across Cellicon Valley. The new site will position Philadelphia as a key lynchpin in biomanufacturing and continue the city’s growth as one of the top biopharma hubs in the United States.
Johnson & Johnson’s pharmaceutical arm, Janssen, embarked on a global effort to combat the COVID-19 pandemic. To support their goal of supplying one billion doses of vaccine, an agreement with a contract manufacturer was reached. Large-scale manufacturing of Janssen’s vaccine would take place at the contract manufacturing site, which is designed for rapid manufacturing of vaccines and other treatments in large quantities during public health emergencies.
Montgomery College Biotechnology: Educating Research and Manufacturing Associates and Scientists for the BioHealth Capital Region
Montgomery College, Maryland’s largest and most diverse community college, provides the BioHealth Capital Region with dozens of qualified research and manufacturing associates each year.
Why Jefferson Institute for Bioprocessing Has Become a Preeminent Model for Biomanufacturing Workforce Training
The Jefferson Institute for Bioprocessing (JIB) is a jewel in the crown of Cellicon Valley. The institute provides critical training in biomanufacturing and bioprocessing for next-generation biologics, vaccines, and cell and gene therapies; skills that are in urgent demand by employers everywhere who are being challenged to find enough experienced employees to sustain their growth.
Pioneering Past Informs Future as Budd Bioworks Unveils 300,000 sq. ft. cGMP BioManufacturing Space in Philadelphia
After Decades of Dormancy, Philadelphia’s Powerhouse Budd Plant Presses Ahead as a New Biomanufacturing Center
PHILADELPHIA, PA July 23, 2021 – A new future is forming around an iconic symbol of Philadelphia’s manufacturing past. The Plymouth Group, in partnership with Centerbridge Partners, L.P., is officially underway on an ambitious biomanufacturing redevelopment plan that puts the life changing therapies developed in Philadelphia’s “Cellicon Valley” on the production line. Spaces will be ready for tenant construction as soon as Q4 of 2021, positioning Philadelphia to meet the swelling demand for cGMP manufacturing nationwide.
The new development will be known as the Budd Campus with the 450,000 square foot Budd Bioworks representing Phase 1 of the project, a life sciences anchor to a 2.4 million square foot adaptive reuse plan that encompasses 6 buildings on over 25 acres in the middle of a major metropolitan area.
Budd Bioworks will comprise 300,000 square feet of cGMP drug manufacturing space along with 150,000 square feet of lab and office space. Residences, restaurants, retail and art activations are planned for subsequent phases within the greater Budd Campus.
Sitting directly between Philadelphia’s Center City and its suburbs, the former Budd Company Hunting Park Plant holds a significant…
GSK is hiring for a large number of full-time jobs to support an expanding portfolio of programs and the growth of their bulk production of several critical drugs manufactured at the site.
We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.
When the Biotechnology Innovation Organization (BIO) convenes its annual trade show this month, Maryland’s life sciences ecosystem, which played a significant role in combating the global COVID-19 pandemic, will be on full display.
Montgomery County (MOCO), Maryland, sits at the epicenter of biopharma growth, investment, and innovation that makes the BioHealth Capital Region (BHCR) one of the top bio clusters in the world.
Life Sciences Talent Pipeline Collaborative